Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 10–11
HOS-086179 · Präparat HOS-083284
Medicinal Product Interactions – Ritonavir with Protease Inhibitors
Co-administered Dose of Co- Dose of Medicinal Product AUC Cmin
Medicinal Product administered NORVIR Assessed
Medicinal (mg)
Product
(mg)
Atazanavir 300 q24h 100 q24h Atazanavir ↑ 86% ↑ 11 fold
1
Atazanavir ↑ 2 fold ↑ 3-7 fold
Ritonavir increases the serum levels of atazanavir as a result of CYP3A4 inhibition.
Clinical trials confirmed the safety and efficacy of 300 mg atazanavir once daily with
ritonavir 100 mg once daily in treatment experienced patients. For further information,
physicians should refer to the SmPC for atazanavir.
Darunavir 600, single 100 q12h Darunavir ↑ 14 fold
Ritonavir increases the serum levels of darunavir as a result of CYP3A inhibition.
Darunavir must be given with ritonavir to ensure its therapeutic effect. Ritonavir doses
higher than 100 mg twice daily have not been studied with darunavir. For further
information, refer to the SmPC for darunavir.
Fosamprenavir 700 q12h 100 q12h Amprenavir ↑ 2.4 ↑ 11 fold
fold
Ritonavir increases the serum levels of amprenavir (from fosamprenavir) as a result of
CYP3A4 inhibition. Fosamprenavir must be given with ritonavir to ensure its therapeutic
effect. Clinical trials confirmed the safety and efficacy of fosamprenavir 700 mg twice
daily with ritonavir 100 mg twice daily. Ritonavir doses higher than 100 mg twice daily
10
have not been studied with fosamprenavir. For further information, physicians should refer
to the SmPC for fosamprenavir.
Indinavir 800 100 q12h Indinavir2 ↑ 178% ND
q12h
Ritonavir ↑ 72% ND
Ritonavir increases the serum levels of indinavir as a result of CYP3A4 inhibition.
Appropriate doses for this combination, with respect to efficacy and safety, have not been
established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is
achieved with doses higher than 100 mg twice daily. In cases of co-administration of
ritonavir (100 mg twice daily) and indinavir (800 mg twice daily) caution is warranted as
the risk of nephrolithiasis may be increased.
Nelfinavir 1250 100 q12h Nelfinavir ↑ ND
q12h 20to39%
Ritonavir increases the serum levels of nelfinavir as a result of CYP3A4 inhibition.
Appropriate doses for this combination, with respect to efficacy and safety, have not been
established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is
achieved with doses higher than 100 mg twice daily.
Tipranavir 500 200 q12h Tipranavir ↑ 11 fold ↑ 29 fold
q12h
Ritonavir ↓ 40% ND
Ritonavir increases the serum levels of tipranavir as a result of CYP3A inhibition.
Tipranavir must be given with low dose ritonavir to ensure its therapeutic effect. Doses of
ritonavir less than 200 mg twice daily should not be used with tipranavir as they might alter
the efficacy of the combination. For further information, physicians should refer to the
SmPC for tipranavir.
ND: Not determined.
1. Based on cross-study comparison to 400 mg atazanavir once daily alone.
2. Based on cross-study comparison to 800 mg indinavir three times daily alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) atazanavir (HOS-086180) nelfinavir (HOS-084520) protease (HOS-085623) amprenavir (HOS-086183) darunavir (HOS-086181) fosamprenavir (HOS-086182) tipranavir (HOS-086184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 03a194213ac89748c50cfb4b51554f8455df8df904ff2077009223828e61e82e · Zeichen 2655–7456 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 43
HOS-086399 · Präparat HOS-083284
Co- Dose of Co- Dose of Medicinal Product AUC Cmin
administered administered NORVIR Assessed
Medicinal Medicinal Product (mg)
Product (mg)
Atazanavir 300 q24h 100 q24h Atazanavir ↑ 86% ↑ 11 fold
1
Atazanavir ↑ 2 fold ↑ 3-7
fold
Ritonavir increases the serum levels of atazanavir as a result of CYP3A4 inhibition. Clinical
trials confirmed the safety and efficacy of 300 mg atazanavir once daily with ritonavir 100 mg
once daily in treatment experienced patients. For further information, physicians should refer
to the SmPC for atazanavir.
Darunavir 600, single 100 q12h Darunavir ↑ 14 fold
Ritonavir increases the serum levels of darunavir as a result of CYP3A inhibition. Darunavir
must be given with ritonavir to ensure its therapeutic effect. Ritonavir doses higher than
100 mg twice daily have not been studied with darunavir. For further information, refer to the
SmPC for darunavir.
Fosamprenavir 700 q12h 100 q12h Amprenavir ↑ 2.4 ↑ 11 fold
fold
Ritonavir increases the serum levels of amprenavir (from fosamprenavir) as a result of
CYP3A4 inhibition. Fosamprenavir must be given with ritonavir to ensure its therapeutic
effect. Clinical trials confirmed the safety and efficacy of fosamprenavir 700 mg twice daily
with ritonavir 100 mg twice daily. Ritonavir doses higher than 100 mg twice daily have not
been studied with fosamprenavir. For further information, physicians should refer to the
SmPC for fosamprenavir.
Indinavir 800 q12h 100 q12h Indinavir2 ↑ 178% ND
Ritonavir ↑ 72% ND
Ritonavir increases the serum levels of indinavir as a result of CYP3A4 inhibition.
Appropriate doses for this combination, with respect to efficacy and safety, have not been
established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is achieved
with doses higher than 100 mg twice daily. In cases of co-administration of ritonavir (100 mg
twice daily) and indinavir (800 mg twice daily) caution is warranted as the risk of
nephrolithiasis may be increased.
Nelfinavir 1250 q12h 100 q12h Nelfinavir ↑ ND
20to39%
Ritonavir increases the serum levels of nelfinavir as a result of CYP3A4 inhibition.
Appropriate doses for this combination, with respect to efficacy and safety, have not been
established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is achieved
with doses higher than 100 mg twice daily.
Tipranavir 500 q12h 200 Tipranavir ↑ 11 fold ↑ 29 fold
q12h
Ritonavir ↓ 40% ND
Ritonavir increases the serum levels of tipranavir as a result of CYP3A inhibition. Tipranavir
must be given with low dose ritonavir to ensure its therapeutic effect. Doses of ritonavir less
than 200 mg twice daily should not be used with tipranavir as they might alter the efficacy of
the combination. For further information, physicians should refer to the SmPC for tipranavir.
ND: Not determined.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) atazanavir (HOS-086180) nelfinavir (HOS-084520) amprenavir (HOS-086183) darunavir (HOS-086181) fosamprenavir (HOS-086182) tipranavir (HOS-086184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage d5308747ba178c6ebd0e34322c465d7122d5458d70aff134d17f324382a8fc16 · Zeichen 2732–7211 im Abschnitt
Wechselwirkungen · Viramune
Viramune 200 mg tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-088094 · Präparat HOS-083615
Darunavir/ritonavir Darunavir AUC 1.24 (0.97-1.57) Darunavir and Viramune can be
400/100 mg BID Darunavir Cmin 1.02 (0.79-1.32) co-administered without dose
Darunavir Cmax 1.40 (1.14-1.73) adjustments.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): darunavir (HOS-086181) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 9055d3e5c1cbdba5a71d018bf47c40b10c25bf2bd4663659c056c1ed2a67f76a · Zeichen 6964–7215 im Abschnitt
Wechselwirkungen · Viramune
Viramune 50 mg/5 mL oral suspension · Abschnitt 4.5 · PDF-Seite 35
HOS-088192 · Präparat HOS-083615
Nevirapine AUC 1.25
(1.17-1.34)
Nevirapine Cmin 1.32 (1.22-1.43)
Nevirapine Cmax 1.17 (1.09-1.25)
Darunavir/ritonavir Darunavir AUC 1.24 (0.97-1.57) Darunavir and Viramune can be
400/100 mg BID Darunavir Cmin 1.02 (0.79-1.32) co-administered without dose
Darunavir Cmax 1.40 (1.14-1.73) adjustments.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): darunavir (HOS-086181) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 217500fd453d0492056097082ed40384e8780e280c03799e08e7adf8399e7e28 · Zeichen 7015–7445 im Abschnitt
Wechselwirkungen · Viramune
Viramune 400 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 60
HOS-088286 · Präparat HOS-083615
Darunavir/ritonavir Darunavir AUC 1.24 (0.97-1.57) Darunavir and Viramune can be
400/100 mg BID Darunavir Cmin 1.02 (0.79-1.32) co-administered without dose
Darunavir Cmax 1.40 (1.14-1.73) adjustments.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): darunavir (HOS-086181) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 9055d3e5c1cbdba5a71d018bf47c40b10c25bf2bd4663659c056c1ed2a67f76a · Zeichen 7284–7535 im Abschnitt
Wechselwirkungen · Viread
Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-110490 · Präparat HOS-093385
Medicinal product by Effects on drug levels Recommendation concerning
therapeutic areas Mean percent change in AUC, co-administration with 245 mg
(dose in mg) Cmax, Cmin tenofovir disoproxil
ANTI-INFECTIVES
Antiretrovirals
Protease inhibitors
Atazanavir/Ritonavir Atazanavir: No dose adjustment is
(300 q.d./100 q.d.) AUC: ↓ 25% recommended. The increased
Cmax: ↓ 28% exposure of tenofovir could
Cmin: ↓ 26% potentiate tenofovir-associated
Tenofovir: adverse events, including renal
AUC: ↑ 37% disorders. Renal function should
Cmax: ↑ 34% be closely monitored
Cmin: ↑ 29% (see section 4.4).
Lopinavir/Ritonavir Lopinavir/ritonavir: No dose adjustment is
(400 b.i.d./100 b.i.d.) No significant effect on recommended. The increased
lopinavir/ritonavir PK exposure of tenofovir could
parameters. potentiate tenofovir-associated
Tenofovir: adverse events, including renal
AUC: ↑ 32% disorders. Renal function should
Cmax: ↔ be closely monitored
Cmin: ↑ 51% (see section 4.4).
Darunavir/Ritonavir Darunavir: No dose adjustment is
(300/100 b.i.d.) No significant effect on recommended. The increased
darunavir/ritonavir PK exposure of tenofovir could
parameters. potentiate tenofovir-associated
Tenofovir: adverse events, including renal
AUC: ↑ 22% disorders. Renal function should
Cmin: ↑ 37% be closely monitored
(see section 4.4).
NRTIs
Didanosine Co-administration of tenofovir Co-administration of tenofovir
disoproxil and didanosine results disoproxil and didanosine is not
in a 40-60% increase in systemic recommended (see section 4.4).
exposure to didanosine.
Increased systemic exposure to
didanosine may increase
didanosine related adverse
reactions. Rarely, pancreatitis and
lactic acidosis, sometimes fatal,
have been reported.
Co-administration of tenofovir
disoproxil and didanosine at a
dose of 400 mg daily has been
associated with a significant
decrease in CD4 cell count,
possibly due to an intracellular
interaction increasing
phosphorylated (i.e. active)
didanosine. A decreased dosage of
250 mg didanosine
co-administered with tenofovir
disoproxil therapy has been
associated with reports of high
rates of virological failure within
several tested combinations for the
treatment of HIV-1 infection.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) lopinavir (HOS-086269) atazanavir (HOS-086180) protease (HOS-085623) didanosine (HOS-085836) darunavir (HOS-086181) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 2da8a9413a0cdf6c2adfbb5e8a3514645ef92df343ae795985c6e470290e6c16 · Zeichen 1811–6985 im Abschnitt
Wechselwirkungen · Viread
Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-110500 · Präparat HOS-093385
10
Medicinal product by Effects on drug levels Recommendation concerning
therapeutic areas Mean percent change in AUC, co-administration with 245 mg
(dose in mg) Cmax, Cmin tenofovir disoproxil
Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma concentrations
(90 mg/400 mg q.d.) + AUC: ↔ of tenofovir resulting from
Darunavir/Ritonavir Cmax: ↔ co-administration of tenofovir
(800 mg q.d./100 mg q.d.) + Cmin: ↔ disoproxil, ledipasvir/sofosbuvir
Emtricitabine/Tenofovir disoproxil and darunavir/ritonavir may
(200 mg/245 mg q.d.)1 Sofosbuvir: increase adverse reactions related
AUC: ↓ 27% to tenofovir disoproxil, including
Cmax: ↓ 37% renal disorders. The safety of
tenofovir disoproxil when used
GS-3310072: with ledipasvir/sofosbuvir and a
AUC: ↔ pharmacokinetic enhancer (e.g.
Cmax: ↔ ritonavir or cobicistat) has not
Cmin: ↔ been established.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) darunavir (HOS-086181) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 087a97d32c6196144fac42069c01c95f98b657dbaf4644b79b530f187480c3be · Zeichen 10060–11640 im Abschnitt
Wechselwirkungen · Viread
Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-110501 · Präparat HOS-093385
Darunavir: The combination should be used
AUC: ↔ with caution with frequent renal
Cmax: ↔ monitoring, if other alternatives
Cmin: ↔ are not available (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): darunavir (HOS-086181)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage ae1d19bd54fc6316b10d526683b7210eb49642c5a7f87bbb4c76a2570c3f9c6a · Zeichen 11679–12048 im Abschnitt
Wechselwirkungen · Viread
Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14–15
HOS-110518 · Präparat HOS-093385
14
Medicinal product by Effects on drug levels Recommendation concerning
therapeutic areas Mean percent change in AUC, co-administration with 245 mg
(dose in mg) Cmax, Cmin tenofovir disoproxil
Sofosbuvir/Velpatasvir Sofosbuvir: Increased plasma concentrations
(400 mg/100 mg q.d.) + AUC: ↓28% of tenofovir resulting from
Darunavir/Ritonavir Cmax: ↓ 38% co-administration of tenofovir
(800 mg q.d./100 mg q.d.) + disoproxil, sofosbuvir/velpatasvir
Emtricitabine/Tenofovir disoproxil GS-3310072: and darunavir/ritonavir may
(200 mg/245 mg q.d.) AUC: ↔ increase adverse reactions related
Cmax: ↔ to tenofovir disoproxil, including
Cmin: ↔ renal disorders. The safety of
tenofovir disoproxil when used
Velpatasvir: with sofosbuvir/velpatasvir and a
AUC: ↔ pharmacokinetic enhancer (e.g.
Cmax: ↓ 24% ritonavir or cobicistat) has not
Cmin: ↔ been established.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) cobicistat (HOS-088111) velpatasvir (HOS-108929) darunavir (HOS-086181) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 737e46afeb9439dde410899a01dd79d8a2f0e067b384f6b1c089de70a2e4dede · Zeichen 20772–22354 im Abschnitt
Wechselwirkungen · Viread
Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15
HOS-110519 · Präparat HOS-093385
Darunavir: The combination should be used
AUC: ↔ with caution with frequent renal
Cmax: ↔ monitoring (see section 4.4).
Cmin: ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): darunavir (HOS-086181)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 1ebe514a8c427442c6b94b51708f115d6b5b0d7c47217dea3fc85e5b0d1ca7c5 · Zeichen 22393–22698 im Abschnitt
Wechselwirkungen · Viread
Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18–19
HOS-110533 · Präparat HOS-093385
18
Medicinal product by Effects on drug levels Recommendation concerning
therapeutic areas Mean percent change in AUC, co-administration with 245 mg
(dose in mg) Cmax, Cmin tenofovir disoproxil
Sofosbuvir/Velpatasvir/ Sofosbuvir: Increased plasma concentrations
Voxilaprevir (400 mg/100 mg/ AUC: ↔ of tenofovir resulting from co-
100 mg+100 mg q.d.)3 + Darunavir Cmax: ↓ 30% administration of tenofovir
(800 mg q.d.) + Ritonavir (100 mg Cmin: N/A disoproxil,
q.d.) + Emtricitabine/Tenofovir sofosbuvir/velpatasvir/voxilaprevir
disoproxil (200 mg/245 mg q.d.) GS-3310072: and darunavir/ritonavir may
AUC: ↔ increase adverse reactions related
Cmax:↔ to tenofovir disoproxil, including
Cmin: N/A renal disorders.
The safety of tenofovir disoproxil
Velpatasvir: when used with
AUC: ↔ sofosbuvir/velpatasvir/voxilaprevir
Cmax: ↔ and a pharmacokinetic enhancer
Cmin: ↔ (e.g. ritonavir or cobicistat) has
not been established.
Voxilaprevir:
AUC: ↑ 143% The combination should be used
Cmax:↑ 72% with caution with frequent renal
Cmin: ↑ 300% monitoring (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) cobicistat (HOS-088111) voxilaprevir (HOS-108930) velpatasvir (HOS-108929) darunavir (HOS-086181) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage d550c8d9097fb86a9733da7c544c1bce662495bf9924cb0e60e96c3044614d33 · Zeichen 31330–33402 im Abschnitt
Wechselwirkungen · Viread
Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 19
HOS-110534 · Präparat HOS-093385
Darunavir:
AUC: ↔
Cmax: ↔
Cmin: ↓ 34%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): darunavir (HOS-086181)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 95963d2db9caeb27548ae923f4719dea27d747c42e659d99b299ec50aa34cedd · Zeichen 33440–33585 im Abschnitt
Wechselwirkungen · Viread
Viread 163 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 48
HOS-110592 · Präparat HOS-093385
Medicinal product by Effects on drug levels Recommendation
therapeutic areas Mean percent change in AUC, Cmax, Cmin concerning
(dose in mg) co-administration with
245 mg tenofovir disoproxil
ANTI-INFECTIVES
Antiretrovirals
Protease inhibitors
Atazanavir/Ritonavir Atazanavir: No dose adjustment is
(300 q.d./100 q.d.) AUC: ↓ 25% recommended. The increased
Cmax: ↓ 28% exposure of tenofovir could
Cmin: ↓ 26% potentiate tenofovir-
Tenofovir: associated adverse events,
AUC: ↑ 37% including renal disorders.
Cmax: ↑ 34% Renal function should be
Cmin: ↑ 29% closely monitored
(see section 4.4).
Lopinavir/Ritonavir Lopinavir/ritonavir: No dose adjustment is
(400 b.i.d./100 b.i.d.) No significant effect on lopinavir/ritonavir recommended. The increased
PK parameters. exposure of tenofovir could
Tenofovir: potentiate tenofovir-
AUC: ↑ 32% associated adverse events,
Cmax: ↔ including renal disorders.
Cmin: ↑ 51% Renal function should be
closely monitored
(see section 4.4).
Darunavir/Ritonavir Darunavir: No dose adjustment is
(300/100 b.i.d.) No significant effect on darunavir/ritonavir recommended. The increased
PK parameters. exposure of tenofovir could
Tenofovir: potentiate tenofovir-
AUC: ↑ 22% associated adverse events,
Cmin: ↑ 37% including renal disorders.
Renal function should be
closely monitored
(see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) lopinavir (HOS-086269) atazanavir (HOS-086180) protease (HOS-085623) darunavir (HOS-086181) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 97402b6653ccc27600d152ec08f35f2adaabc6d7df63e20237baf32481f6489e · Zeichen 1810–4982 im Abschnitt
Wechselwirkungen · Viread
Viread 163 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 50–51
HOS-110599 · Präparat HOS-093385
50
Medicinal product by Effects on drug levels Recommendation
therapeutic areas Mean percent change in AUC, Cmax, Cmin concerning
(dose in mg) co-administration with
245 mg tenofovir disoproxil
Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma
(90 mg/400 mg q.d.) + AUC: ↔ concentrations of tenofovir
Darunavir/Ritonavir Cmax: ↔ resulting from
(800 mg q.d./100 mg q.d.) + Cmin: ↔ co-administration of tenofovir
Emtricitabine/Tenofovir disoproxil,
disoproxil Sofosbuvir: ledipasvir/sofosbuvir and
(200 mg/245 mg q.d.)1 AUC: ↓ 27% darunavir/ritonavir may
Cmax: ↓ 37% increase adverse reactions
related to tenofovir disoproxil,
GS-3310072: including renal disorders. The
AUC: ↔ safety of tenofovir disoproxil
Cmax: ↔ when used with
Cmin: ↔ ledipasvir/sofosbuvir and a
pharmacokinetic enhancer
Darunavir: (e.g. ritonavir or cobicistat)
AUC: ↔ has not been established.
Cmax: ↔
Cmin: ↔ The combination should be
used with caution with
Ritonavir: frequent renal monitoring, if
AUC: ↔ other alternatives are not
Cmax: ↔ available (see section 4.4).
Cmin: ↑ 48%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) darunavir (HOS-086181) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage bdbba031567de86e144e97b81ef760d77dfbe989e81af41ca7d35743864c2e03 · Zeichen 11841–14333 im Abschnitt
Wechselwirkungen · Viread
Viread 163 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 54–55
HOS-110613 · Präparat HOS-093385
54
Medicinal product by Effects on drug levels Recommendation
therapeutic areas Mean percent change in AUC, Cmax, Cmin concerning
(dose in mg) co-administration with
245 mg tenofovir disoproxil
Sofosbuvir/Velpatasvir Sofosbuvir: Increased plasma
(400 mg/100 mg q.d.) + AUC: ↓28% concentrations of tenofovir
Darunavir/Ritonavir Cmax: ↓ 38% resulting from
(800 mg q.d./100 mg q.d.) + co-administration of tenofovir
Emtricitabine/Tenofovir GS-3310072: disoproxil,
disoproxil AUC: ↔ sofosbuvir/velpatasvir and
(200 mg/245 mg q.d.) Cmax: ↔ darunavir/ritonavir may
Cmin: ↔ increase adverse reactions
related to tenofovir disoproxil,
Velpatasvir: including renal disorders. The
AUC: ↔ safety of tenofovir disoproxil
Cmax: ↓ 24% when used with
Cmin: ↔ sofosbuvir/velpatasvir and a
pharmacokinetic enhancer
Darunavir: (e.g. ritonavir or cobicistat)
AUC: ↔ has not been established.
Cmax: ↔
Cmin: ↔ The combination should be
used with caution with
Ritonavir: frequent renal monitoring (see
AUC: ↔ section 4.4).
Cmax: ↔
Cmin: ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) cobicistat (HOS-088111) velpatasvir (HOS-108929) darunavir (HOS-086181) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage e6335f4176b98a52989a9f36192d67ce8031012747a37072e892d128b679320b · Zeichen 23244–25660 im Abschnitt
Wechselwirkungen · Viread
Viread 163 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 58–59
HOS-110627 · Präparat HOS-093385
58
Medicinal product by Effects on drug levels Recommendation
therapeutic areas Mean percent change in AUC, Cmax, Cmin concerning
(dose in mg) co-administration with
245 mg tenofovir disoproxil
Sofosbuvir/Velpatasvir/ Sofosbuvir: Increased plasma
Voxilaprevir (400 mg/100 mg/ AUC: ↔ concentrations of tenofovir
100 mg+100 mg q.d.)3 + Cmax: ↓ 30% resulting from co-
Darunavir (800 mg q.d.) + Cmin: N/A administration of tenofovir
Ritonavir (100 mg q.d.) + disoproxil,
Emtricitabine/Tenofovir GS-3310072: sofosbuvir/velpatasvir/voxilap
disoproxil (200 mg/245 mg q.d.) AUC: ↔ revir and darunavir/ritonavir
Cmax:↔ may increase adverse
Cmin: N/A reactions related to tenofovir
disoproxil, including renal
Velpatasvir: disorders.
AUC: ↔ The safety of tenofovir
Cmax: ↔ disoproxil when used with
Cmin: ↔ sofosbuvir/velpatasvir/voxilap
revir and a pharmacokinetic
Voxilaprevir: enhancer (e.g. ritonavir or
AUC: ↑ 143% cobicistat) has not been
Cmax:↑ 72% established.
Cmin: ↑ 300%
The combination should be
Darunavir: used with caution with
AUC: ↔ frequent renal monitoring (see
Cmax: ↔ section 4.4).
Cmin: ↓ 34%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) cobicistat (HOS-088111) voxilaprevir (HOS-108930) velpatasvir (HOS-108929) darunavir (HOS-086181) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 8f90c3405a909c8e9cd0f1c3dec1c93cb05981de545d195f7ffe4f8d2624fc77 · Zeichen 34101–36770 im Abschnitt
Wechselwirkungen · Viread
Viread 204 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 88
HOS-110683 · Präparat HOS-093385
Medicinal product by Effects on drug levels Recommendation
therapeutic areas Mean percent change in AUC, Cmax, Cmin concerning
(dose in mg) co-administration with
245 mg tenofovir disoproxil
ANTI-INFECTIVES
Antiretrovirals
Protease inhibitors
Atazanavir/Ritonavir Atazanavir: No dose adjustment is
(300 q.d./100 q.d.) AUC: ↓ 25% recommended. The increased
Cmax: ↓ 28% exposure of tenofovir could
Cmin: ↓ 26% potentiate tenofovir-
Tenofovir: associated adverse events,
AUC: ↑ 37% including renal disorders.
Cmax: ↑ 34% Renal function should be
Cmin: ↑ 29% closely monitored
(see section 4.4).
Lopinavir/Ritonavir Lopinavir/ritonavir: No dose adjustment is
(400 b.i.d./100 b.i.d.) No significant effect on lopinavir/ritonavir recommended. The increased
PK parameters. exposure of tenofovir could
Tenofovir: potentiate tenofovir-
AUC: ↑ 32% associated adverse events,
Cmax: ↔ including renal disorders.
Cmin: ↑ 51% Renal function should be
closely monitored
(see section 4.4).
Darunavir/Ritonavir Darunavir: No dose adjustment is
(300/100 b.i.d.) No significant effect on darunavir/ritonavir recommended. The increased
PK parameters. exposure of tenofovir could
Tenofovir: potentiate tenofovir-
AUC: ↑ 22% associated adverse events,
Cmin: ↑ 37% including renal disorders.
Renal function should be
closely monitored
(see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) lopinavir (HOS-086269) atazanavir (HOS-086180) protease (HOS-085623) darunavir (HOS-086181) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 97402b6653ccc27600d152ec08f35f2adaabc6d7df63e20237baf32481f6489e · Zeichen 1810–4982 im Abschnitt
Wechselwirkungen · Viread
Viread 204 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 90–91
HOS-110689 · Präparat HOS-093385
90
Medicinal product by Effects on drug levels Recommendation
therapeutic areas Mean percent change in AUC, Cmax, Cmin concerning
(dose in mg) co-administration with
245 mg tenofovir disoproxil
Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma
(90 mg/400 mg q.d.) + AUC: ↔ concentrations of tenofovir
Darunavir/Ritonavir Cmax: ↔ resulting from
(800 mg q.d./100 mg q.d.) + Cmin: ↔ co-administration of tenofovir
Emtricitabine/Tenofovir disoproxil,
disoproxil Sofosbuvir: ledipasvir/sofosbuvir and
(200 mg/245 mg q.d.)1 AUC: ↓ 27% darunavir/ritonavir may
Cmax: ↓ 37% increase adverse reactions
related to tenofovir disoproxil,
GS-3310072: including renal disorders. The
AUC: ↔ safety of tenofovir disoproxil
Cmax: ↔ when used with
Cmin: ↔ ledipasvir/sofosbuvir and a
pharmacokinetic enhancer
Darunavir: (e.g. ritonavir or cobicistat)
AUC: ↔ has not been established.
Cmax: ↔
Cmin: ↔ The combination should be
used with caution with
Ritonavir: frequent renal monitoring, if
AUC: ↔ other alternatives are not
Cmax: ↔ available (see section 4.4).
Cmin: ↑ 48%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) darunavir (HOS-086181) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage e284358b6ca38a0282224d92c8c26b67e60192ffc14ae6f0af344817caf4e595 · Zeichen 11841–14333 im Abschnitt
Wechselwirkungen · Viread
Viread 204 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 94–95
HOS-110703 · Präparat HOS-093385
94
Medicinal product by Effects on drug levels Recommendation
therapeutic areas Mean percent change in AUC, Cmax, Cmin concerning
(dose in mg) co-administration with
245 mg tenofovir disoproxil
Sofosbuvir/Velpatasvir Sofosbuvir: Increased plasma
(400 mg/100 mg q.d.) + AUC: ↓28% concentrations of tenofovir
Darunavir/Ritonavir Cmax: ↓ 38% resulting from
(800 mg q.d./100 mg q.d.) + co-administration of tenofovir
Emtricitabine/Tenofovir GS-3310072: disoproxil,
disoproxil AUC: ↔ sofosbuvir/velpatasvir and
(200 mg/245 mg q.d.) Cmax: ↔ darunavir/ritonavir may
Cmin: ↔ increase adverse reactions
related to tenofovir disoproxil,
Velpatasvir: including renal disorders. The
AUC: ↔ safety of tenofovir disoproxil
Cmax: ↓ 24% when used with
Cmin: ↔ sofosbuvir/velpatasvir and a
pharmacokinetic enhancer
Darunavir: (e.g. ritonavir or cobicistat)
AUC: ↔ has not been established.
Cmax: ↔
Cmin: ↔ The combination should be
used with caution with
Ritonavir: frequent renal monitoring (see
AUC: ↔ section 4.4).
Cmax: ↔
Cmin: ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) cobicistat (HOS-088111) velpatasvir (HOS-108929) darunavir (HOS-086181) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 44481f5a7aa3f713b8da7f6a789ab70c5b5e13f18cb6b4519cc7c72f41e756c6 · Zeichen 23244–25660 im Abschnitt
Wechselwirkungen · Viread
Viread 204 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 98–99
HOS-110717 · Präparat HOS-093385
98
Medicinal product by Effects on drug levels Recommendation
therapeutic areas Mean percent change in AUC, Cmax, Cmin concerning
(dose in mg) co-administration with
245 mg tenofovir disoproxil
Sofosbuvir/Velpatasvir/ Sofosbuvir: Increased plasma
Voxilaprevir (400 mg/100 mg/ AUC: ↔ concentrations of tenofovir
100 mg+100 mg q.d.)3 + Cmax: ↓ 30% resulting from co-
Darunavir (800 mg q.d.) + Cmin: N/A administration of tenofovir
Ritonavir (100 mg q.d.) + disoproxil,
Emtricitabine/Tenofovir GS-3310072: sofosbuvir/velpatasvir/voxilap
disoproxil (200 mg/245 mg q.d.) AUC: ↔ revir and darunavir/ritonavir
Cmax:↔ may increase adverse
Cmin: N/A reactions related to tenofovir
disoproxil, including renal
Velpatasvir: disorders.
AUC: ↔ The safety of tenofovir
Cmax: ↔ disoproxil when used with
Cmin: ↔ sofosbuvir/velpatasvir/voxilap
revir and a pharmacokinetic
Voxilaprevir: enhancer (e.g. ritonavir or
AUC: ↑ 143% cobicistat) has not been
Cmax:↑ 72% established.
Cmin: ↑ 300%
The combination should be
Darunavir: used with caution with
AUC: ↔ frequent renal monitoring (see
Cmax: ↔ section 4.4).
Cmin: ↓ 34%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) cobicistat (HOS-088111) voxilaprevir (HOS-108930) velpatasvir (HOS-108929) darunavir (HOS-086181) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 08bfdc9714ebdae009fc223c2883980eb82fdcfb11046f8927ba2c44153bbf0d · Zeichen 34101–36770 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.